Microbiome-based informed method to formulate live biotherapeutics

    公开(公告)号:US20210220413A1

    公开(公告)日:2021-07-22

    申请号:US17223710

    申请日:2021-04-06

    IPC分类号: A61K35/742

    摘要: Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.

    Microbiome-based informed method to formulate live biotherapeutics

    公开(公告)号:US20200330529A1

    公开(公告)日:2020-10-22

    申请号:US16917661

    申请日:2020-06-30

    IPC分类号: A61K35/742

    摘要: Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.

    Microbiome-based informed method to formulate live biotherapeutics

    公开(公告)号:US20240033306A1

    公开(公告)日:2024-02-01

    申请号:US18045066

    申请日:2022-10-07

    IPC分类号: A61K35/742

    CPC分类号: A61K35/742 A61K35/74

    摘要: Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.

    Microbiome-based informed method to formulate live biotherapeutics

    公开(公告)号:US20200227139A1

    公开(公告)日:2020-07-16

    申请号:US16800702

    申请日:2020-02-25

    IPC分类号: G16B30/20 C12N9/00 A61K35/742

    摘要: Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.

    Microbiome-based informed method to formulate live biotherapeutics

    公开(公告)号:US20210244776A1

    公开(公告)日:2021-08-12

    申请号:US17223754

    申请日:2021-04-06

    IPC分类号: A61K35/742

    摘要: Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.

    Microbiome-based informed method to formulate live biotherapeutics

    公开(公告)号:US11037655B2

    公开(公告)日:2021-06-15

    申请号:US16800702

    申请日:2020-02-25

    摘要: Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.

    Microbiome-based informed method to formulate live biotherapeutics

    公开(公告)号:US10967012B2

    公开(公告)日:2021-04-06

    申请号:US16917661

    申请日:2020-06-30

    摘要: Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.